Dry Eye

According to Allgenesis Biotherapeutics, AG-8030 is a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of DED.

Dry eye experts discuss the future of dry eye management.

Dry eye experts discuss Cyclosporine ophthalmic solution.

Dry eye experts discuss how they use a comprehensive dry eye diagnostic approach to tailor and customize individual patients.

Dry eye experts discuss how they tailor dry eye treatment based on diagnostic test results and other factors.

Dry eye experts discuss how they use a comprehensive dry eye diagnostic approach to tailor and customize individual patients.

Dry eye experts discuss how they use a comprehensive dry eye diagnostic approach to tailor and customize individual patients.

Dry eye experts discuss tear film assessment techniques and emphasize the importance of distinguishing between aqueous-deficient and evaporative dry eye for targeted treatment approaches.

The collaboration agreement will allow the 2 companies to find a potential new treatment for chronic dry eye disease.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

TFI employs spectral interference technology to image and map the corneal surface.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.

Prevent Blindness is offering educational resources and will partner with OCuSOFT Inc. in support of Dry Eye Awareness Month in July.

Alice Epitropoulos, MD, and Laura M. Periman, MD, share insights on the various diagnostic tests they employ for patients exhibiting dry eye symptoms.

Physicians wonder whether normal examination results are actually normal.

Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.

The trial is designed to enable a resubmission of a New Drug Application to the US FDA for reproxalap after receiving a Complete Response Letter last year.

According to the company, it will finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

The trial aims to evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment (AZR-MD-001) 0.5% compared to vehicle in patients with abnormal meibomian gland function (MGD) and associated symptoms of dry eye disease (DED)

According to the company, the data demonstrates sustained safety and efficacy in the treatment of the signs and symptoms in patients diagnosed with dry eye disease.

The gel is a cross-linked hyaluronic acid derivative and has been cleared by the FDA to temporarily block tear drainage by the occlusion of the canalicular system.

The launch of Blink NutriTears follows a clinical trial that demonstrated improved ocular symptom severity and tear film homeostasis, and that it helped tears stay on the eyes for 33% longer

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with dry eye disease.

The trial is a study of twice daily tanfanercept ophthalmic solution 0.25% and 1.0% and will leverage key insights from the concluded Phase III VELOS-3 study.